CoChat

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study

Open access

Published version of a preprint

Abstract

BACKGROUND: The past two decades have seen expansion of childhood vaccination programmes in low-income and middle-income countries (LMICs). We quantify the health impact of these programmes by estimating the deaths and disability-adjusted life-years (DALYs) averted by vaccination against ten pathogens in 98 LMICs between 2000 and 2030. METHODS: 16 independent research groups provided model-based disease burden estimates under a range of vaccination coverage scenarios for ten pathogens: hepatitis B virus, Haemophilus influenzae type B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, Streptococcus pneumoniae, rotavirus, rubella, and yellow fever. Using standardised demographic data and vaccine coverage, the impact of vaccination programmes was determined by comparing model estimates from a no-vaccination counterfactual scenario with those from a reported and projected vaccination scenario. We present deaths and DALYs averted between 2000 and 2030 by calendar year and by annual birth cohort. FINDINGS: We estimate that vaccination of the ten selected pathogens will have averted 69 million (95% credible interval 52-88) deaths between 2000 and 2030, of which 37 million (30-48) were averted between 2000 and 2019. From 2000 to 2019, this represents a 45% (36-58) reduction in deaths compared with the counterfactual scenario of no vaccination. Most of this impact is concentrated in a reduction in mortality among children younger than 5 years (57% reduction [52-66]), most notably from measles. Over the lifetime of birth cohorts born between 2000 and 2030, we predict that 120 million (93-150) deaths will be averted by vaccination, of which 58 million (39-76) are due to measles vaccination and 38 million (25-52) are due to hepatitis B vaccination. We estimate that increases in vaccine coverage and introductions of additional vaccines will result in a 72% (59-81) reduction in lifetime mortality in the 2019 birth cohort. INTERPRETATION: Increases in vaccine coverage and the introduction of new vaccines into LMICs have had a major impact in reducing mortality. These public health gains are predicted to increase in coming decades if progress in increasing coverage is sustained. FUNDING: Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)32657-x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Vaccine coverage across the ten pathogens considered Vaccine coverage, calculated as the mean number of vaccines received per child born in a specific year, is shown for 2000 (A), 2010 (B), and 2019 (C). The colour scale shows the expected number of vaccines received per child in each country. (D) Routine vaccine coverage for each pathogen, from 2000 to 2019, averaged across all 98 countries, except for Japanese encephalitis, Neisseria meningitidis serogroup A, and yellow fever, which were averaged across the 16, 26, and 32 endemic countries for those pathogens, respectively. The average was obtained by dividing total vaccine doses by the total eligible population. PCV=pneumococcal conjugate vaccine.
Figure 1 Vaccine coverage across the ten pathogens considered Vaccine coverage, calculated as the mean number of vaccines received per child born in a specific year, is shown for 2000 (A), 2010 (B), and 2019 (C). The colour scale shows the expected number of vaccines received per child in each country. (D) Routine vaccine coverage for each pathogen, from 2000 to 2019, averaged across all 98 countries, except for Japanese encephalitis, Neisseria meningitidis serogroup A, and yellow fever, which were averaged across the 16, 26, and 32 endemic countries for those pathogens, respectively. The average was obtained by dividing total vaccine doses by the total eligible population. PCV=pneumococcal conjugate vaccine.CC BY · PubMed Central
Figure 2 Estimates of disease-specific deaths by calendar year, from 2000 to 2030, across 98 countries, for reported and projected vaccine coverage and counterfactual (no vaccination) coverage Lines show estimates of deaths for the two scenarios, for all ages. The corresponding shaded areas show the 95% credible intervals (2·5% and 97·5% quantiles). The grey shaded parts show the area where the 95% credible intervals for the two scenarios overlap. PCV=pneumococcal conjugate vaccine.
Figure 2 Estimates of disease-specific deaths by calendar year, from 2000 to 2030, across 98 countries, for reported and projected vaccine coverage and counterfactual (no vaccination) coverage Lines show estimates of deaths for the two scenarios, for all ages. The corresponding shaded areas show the 95% credible intervals (2·5% and 97·5% quantiles). The grey shaded parts show the area where the 95% credible intervals for the two scenarios overlap. PCV=pneumococcal conjugate vaccine.CC BY · PubMed Central
Figure 3 Estimates of deaths averted by vaccination in 98 countries (A) Estimates of death averted by calendar year (summing across all ages) and pathogen. (B) Estimates of deaths averted by year of birth (summing across lifetime) and pathogen. (C) Proportion of lifetime deaths due to the ten pathogens considered in the no-vaccination counterfactual scenario that are predicted to be averted by vaccination, by country, across 2000–19 birth cohorts. PCV=pneumococcal conjugate vaccine.
Figure 3 Estimates of deaths averted by vaccination in 98 countries (A) Estimates of death averted by calendar year (summing across all ages) and pathogen. (B) Estimates of deaths averted by year of birth (summing across lifetime) and pathogen. (C) Proportion of lifetime deaths due to the ten pathogens considered in the no-vaccination counterfactual scenario that are predicted to be averted by vaccination, by country, across 2000–19 birth cohorts. PCV=pneumococcal conjugate vaccine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 300

Metadata

Authors
Li, X., Mukandavire, C., Cucunubá, Z. M., Echeverria Londono, S., Abbas, K., Clapham, H. E., Jit, M., Johnson, H. L., Papadopoulos, T., Vynnycky, E., Brisson, M., Carter, E. D., Clark, A., de Villiers, M. J., Eilertson, K., Ferrari, M. J., Gamkrelidze, I., Gaythorpe, K. A. M., Grassly, N. C., Hallett, T. B., Hinsley, W., Jackson, M. L., Jean, K., Karachaliou, A., Klepac, P., Lessler, J., Li, X., Moore, S. M., Nayagam, S., Nguyen, D. M., Razavi, H., Razavi-Shearer, D., Resch, S., Sanderson, C., Sweet, S., Sy, S., Tam, Y., Tanvir, H., Tran, Q. M., Trotter, C. L., Truelove, S., van Zandvoort, K., Verguet, S., Walker, N., Winter, A., Woodruff, K., Ferguson, N. M., & Garske, T.
Affiliations
  • Imperial College London (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • National University of Singapore (SG)
  • Public Health England (GB)
  • Gavi (CH)
  • Université Laval (CA)
  • Johns Hopkins University (US)
  • Colorado State University (US)
  • Pennsylvania State University (US)
  • Center for Disease Analysis (US)
  • Kaiser Permanente (US)
  • Conservatoire National des Arts et Métiers (FR)
  • University of Cambridge (GB)
  • University of Notre Dame (US)
  • Oxford University Clinical Research Unit (VN)
  • Harvard University (US)
Corresponding author
Ferguson, Neil M
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-01
Volume
397
Issue
10272
Pages
398-408
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3123481858
Cited by
300
References
24
Citations by year
2026: 39 · 2025: 50 · 2024: 49 · 2023: 65 · 2022: 48 · 2021: 44
FWCI
28.56
Type
journal article
Language
en
Update notices
erratum (2021-02-20)
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • National University of Singapore (submittedVersion, cc-by)
  • HAL (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
  • Greater South Information System
Funders
  • GAVI Alliance
  • Bill and Melinda Gates Foundation
Topics
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Global Maternal and Child Health
Keywords
childhood immunization, vaccine impact, mortality averted, disability-adjusted life years, measles vaccination, hepatitis B vaccination, Haemophilus influenzae type b, human papillomavirus, Japanese encephalitis, Neisseria meningitidis serogroup A, Streptococcus pneumoniae, rotavirus, rubella, yellow fever, low- and middle-income countries
MeSH terms
Child, Preschool, Communicable Disease Control, Communicable Diseases, Cost-Benefit Analysis, Developing Countries, Female, Humans, Male, Models, Theoretical, Mortality, Vaccination, Global Health, Immunization Programs, Quality-Adjusted Life Years

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32657-x
The paper
Li, X., Mukandavire, C., Cucunubá, Z. M., Echeverria Londono, S., Abbas, K., Clapham, H. E., Jit, M., Johnson, H. L., Papadopoulos, T., Vynnycky, E., Brisson, M., Carter, E. D., Clark, A., de Villiers, M. J., Eilertson, K., Ferrari, M. J., Gamkrelidze, I., Gaythorpe, K. A. M., Grassly, N. C., . . . Garske, T. (2021). Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. The Lancet. https://doi.org/10.1016/s0140-6736(20)32657-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.